Kharitonov 1996.

Methods	Setting: UK, hospital outpatient clinic Randomisation: yes, method not stated Allocation concealment: unclear Design: crossover, 3 week washout Intervention period: 3 weeks Masking: double blind Excluded: not stated Withdrawals: not stated Baseline characteristics: comparable Jadad score=2
Participants	11 adults: 8M 3F Age range: 26‐36 years Inclusion criteria: Atopic asthma Positive skin prick test to at least 2 allergens FEV1 (% predicted) >70 Methacholine BHR (PC20 FEV1) < 8 mg/ml Exclusion criteria: Regular oral or inhaled steroid use Respiratory tract infection or asthma exacerbation in last month
Interventions	BUD: 800 mcg 2xdaily (1600 mcg/d) Placebo: 2xdaily Delivery device: Turbohaler DPI
Outcomes	FEV1 (% predicted) Methacholine BHR (PC20 FEV1) Exhaled air nitric oxide concentration
Notes	No reply from author to clarify details of randomisation method.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear